New Parkinson's infusion tested in everyday clinics
NCT ID NCT07382440
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 120 adults with advanced Parkinson's disease in Belgium who are prescribed a drug called Foslevodopa/Foscarbidopa. The drug is given as a continuous infusion under the skin to help control symptoms. Researchers will track how much 'off' time (when symptoms like tremors and stiffness return) patients experience over 18 months in routine care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Foslevodopa/Foscarbidopa
What this could lead to
If successful, this study could confirm that this drug infusion effectively reduces 'off' time (when symptoms return) for advanced Parkinson's patients in everyday care.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It only includes 120 people in Belgium, so findings may not apply to everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AZ Oostende /ID# 279461
RECRUITINGOstend, West-Vlaanderen, 8400, Belgium
-
AZ Sint-Lucas /ID# 279453
RECRUITINGGhent, Oost-Vlaanderen, 9000, Belgium
-
AZ-Delta. /ID# 279437
RECRUITINGRoeselare, West-Vlaanderen, 8800, Belgium
-
Algemeen Ziekenhuis Sint-Jan Brugge /ID# 279422
RECRUITINGBruges, West-Vlaanderen, 8000, Belgium
-
Az Groeninge Campus Kennedylaan /ID# 279423
RECRUITINGKortrijk, West-Vlaanderen, 8500, Belgium
-
Centre Hospitalier De Wallonie Picarde - Site Notre Dame /ID# 279452
RECRUITINGTournai, Hainaut, 7500, Belgium
-
Chu Tivoli /ID# 279455
RECRUITINGLa Louvière, Hainaut, 7100, Belgium
-
Imelda Ziekenhuis /ID# 279436
RECRUITINGBonheiden, Antwerpen, 2820, Belgium
-
Jessa Ziekenhuis - Campus Virga Jesse /ID# 279454
RECRUITINGHasselt, Limburg, 3500, Belgium
-
UZ Gent /ID# 279433
RECRUITINGGhent, Oost-Vlaanderen, 9000, Belgium
-
Universitair Ziekenhuis Antwerpen /ID# 279434
RECRUITINGEdegem, Antwerpen, 2650, Belgium
-
Universitair Ziekenhuis Leuven /ID# 279439
RECRUITINGLeuven, Vlaams-Brabant, 3000, Belgium